Loading AXSM detail
Loading ticker data...
Loading AXSM detail
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States.
The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Chart data unavailable
Axsome Therapeutics, Inc. (NASDAQ: AXSM - Get Free Report) has been given an average recommendation of "Moderate Buy" by the twenty research firms that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, seventeen have assigned a buy rating and one has given a strong buy rating to
Axsome Therapeutics has performed well since its IPO. The company's current lineup and pipeline could drive growth for a while.
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the first quarter of 2026 on Monday, May 4, 2026, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update.
SG Americas Securities LLC lifted its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) by 46.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 17,681 shares of the company's stock after purchasing an additional 5,584 shares during the period.
Summit Therapeutics shares could drop later this year if it doesn't earn approval for its leading candidate. Madrigal Pharmaceuticals and Axsome Therapeutics could move in the opposite direction.
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
PTC Therapeutics (NASDAQ: PTCT - Get Free Report) and Axsome Therapeutics (NASDAQ: AXSM - Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations. Insider and Institutional Ownership 81.5% of Axsome
Superstring Capital Management purchased 37,433 shares of Axsome Therapeutics in the fourth quarter. The quarter-end position value was $6.84 million, representing a new holding in Axsome Therapeutics.
Axsome's lead product, Auvelity, sales jumped 74% to $507M in 2025, fueling growth while other drugs added momentum.
Axsome Therapeutics, Inc. (AXSM) Presents at The Citizens Life Sciences Conference 2026 Transcript
Axsome Therapeutics, Inc. (AXSM) Presents at Leerink Global Healthcare Conference 2026 Transcript
Axsome Therapeutics has an exciting late-stage pipeline. Madrigal Pharmaceuticals is looking to dominate a large market with significant unmet needs.
32,410 shares were exercised and sold for a total transaction value of ~$6.0 million on February 2, 2026. After this transaction, Tabuteau directly held 7,229 shares and indirectly held 7,344,500 shares.
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in March:
Axsome misses Q4 estimates for earnings. Revenues jump 65% on strong Auvelity sales as well as other product sales and top estimates.
